Cargando…

Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk

Type 2 diabetes (T2D) with increasing prevalence is a significant global public health challenge. Obesity, unhealthy diet, and low physical activity are one of the major determinants of the rise in T2D prevalence. In addition, family history and genetic risk of diabetes also play a role in the proce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martikainen, Janne, Lehtimäki, Aku-Ville, Jalkanen, Kari, Lavikainen, Piia, Paajanen, Teemu, Marjonen, Heidi, Kristiansson, Kati, Lindström, Jaana, Perola, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520240/ https://www.ncbi.nlm.nih.gov/pubmed/36186460 http://dx.doi.org/10.3389/fgene.2022.880799

Ejemplares similares

Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis
por: Jalkanen, Kari, et al.
Publicado: (2021)

Type 2 Diabetes-Related Health Economic Impact Associated with Increased Whole Grains Consumption among Adults in Finland
por: Martikainen, Janne, et al.
Publicado: (2021)

A Web Portal for Communicating Polygenic Risk Score Results for Health Care Use—The P5 Study
por: Marjonen, Heidi, et al.
Publicado: (2021)

Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5 L index scores in the Finnish population
por: Jalkanen, Kari, et al.
Publicado: (2019)

Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes
por: Lavikainen, Piia, et al.
Publicado: (2020)

Data-driven long-term glycaemic control trajectories and their associated health and economic outcomes in Finnish patients with incident type 2 diabetes
por: Lavikainen, Piia, et al.
Publicado: (2022)

Hospital treatment costs associated with incident complications in patients with type 2 diabetes—real-world study based on electronic patient information systems
por: Sund, Reijo, et al.
Publicado: (2022)

Willingness to Pay for Implementation of an Environmentally Friendly Pharmaceutical Policy in Finland—A Discrete Choice Experiment Study
por: Alajärvi, Lasse, et al.
Publicado: (2022)

Psychosocial Effects of Receiving Genome-Wide Polygenic Risk Information Concerning Type 2 Diabetes and Coronary Heart Disease: A Randomized Controlled Trial
por: Halmesvaara, Otto, et al.
Publicado: (2022)

LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model
por: Inglin, Laura, et al.
Publicado: (2021)

Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study
por: Åberg, Fredrik, et al.
Publicado: (2022)

The association between Planetary Health Diet, body mass index and polygenic risk score for obesity
por: Suikki, T, et al.
Publicado: (2023)

Effects of COVID-19 Pandemic and Lockdown on Monitoring and Treatment Balance of Finnish Coronary Heart Disease and Type 2 Diabetes Patients
por: Lavikainen, Piia, et al.
Publicado: (2022)

Marked Improvement in A1C Levels After Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Maintained Over 4 Years in Patients With Type 1 Diabetes
por: Mustonen, Jyrki, et al.
Publicado: (2022)

The use of isCGM leads to marked reduction in severe hypoglycemia requiring emergency medical service or hospital admission and diabetic ketoacidosis in adult type 1 diabetes patients
por: Mustonen, Jyrki, et al.
Publicado: (2023)

Comparison of Communication Channels for Large-Scale Type 2 Diabetes Risk Screening and Intervention Recruitment: Empirical Study
por: Jalkanen, Kari, et al.
Publicado: (2021)

Polygenic Risk Scores and Physical Activity
por: KUJALA, URHO M., et al.
Publicado: (2020)

Statin adherence and risk of acute cardiovascular events among women: a cohort study accounting for time-dependent confounding affected by previous adherence
por: Lavikainen, Piia, et al.
Publicado: (2016)

Data-Driven Identification of Long-Term Glycemia Clusters and Their Individualized Predictors in Finnish Patients with Type 2 Diabetes
por: Lavikainen, Piia, et al.
Publicado: (2023)

Agreement between physician- and patient-reported Canadian cardiovascular society scores among patients undergoing elective coronary angiography–The CATS study
por: Lavikainen, Piia, et al.
Publicado: (2023)

Digitally Supported Lifestyle Intervention to Prevent Type 2 Diabetes Through Healthy Habits: Secondary Analysis of Long-Term User Engagement Trajectories in a Randomized Controlled Trial
por: Lavikainen, Piia, et al.
Publicado: (2022)

Medicine use in children aged under 12 years—Population survey in Finland
por: Kesti, Joonas, et al.
Publicado: (2022)

Correlation of the disease-specific Canadian Cardiovascular Society (CCS) classification and health-related quality of life (15D) in coronary artery disease patients
por: Kotajärvi, Jarno, et al.
Publicado: (2022)

Accumulation of Cardiovascular and Diabetes Medication among Apparently Healthy Statin Initiators
por: Lavikainen, Piia, et al.
Publicado: (2015)

Patient-reported outcomes in coronary artery disease: the relationship between the standard, disease-specific set by the International Consortium for Health Outcomes Measurement (ICHOM) and the generic health-related quality of life instrument 15D
por: Lappalainen, Laura, et al.
Publicado: (2021)

Association Between Polygenic Risk Score and Risk of Myopia
por: Ghorbani Mojarrad, Neema, et al.
Publicado: (2019)

Polygenic risk scores in the clinic: Translating risk into action
por: Lewis, Anna C.F., et al.
Publicado: (2021)

Polygenic Risk Score and Risk Factors for Gestational Diabetes
por: Perišić, Marija Majda, et al.
Publicado: (2022)

Polygenic risk scores and breast cancer risk prediction
por: Roberts, Eleanor, et al.
Publicado: (2023)

Potential use of clinical polygenic risk scores in psychiatry – ethical implications and communicating high polygenic risk
por: Palk, A. C., et al.
Publicado: (2019)

Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk scores across ancestries
por: Liang, Yanyu, et al.
Publicado: (2022)

History of Medically Treated Diabetes and Risk of Alzheimer Disease in a Nationwide Case-Control Study
por: Tolppanen, Anna-Maija, et al.
Publicado: (2013)

Associations of polygenic risk scores for preeclampsia and blood pressure with hypertensive disorders of pregnancy
por: Nurkkala, Jouko, et al.
Publicado: (2023)

PRSice: Polygenic Risk Score software
por: Euesden, Jack, et al.
Publicado: (2015)

Polygenic Hypercholesterolemia and Cardiovascular Disease Risk
por: Sharifi, Mahtab, et al.
Publicado: (2019)

Polygenic risk and pleiotropy in neurodegenerative diseases
por: Bellou, Eftychia, et al.
Publicado: (2020)

Polygenic Risk Scores for Subtyping of Schizophrenia
por: Chen, Jingchun, et al.
Publicado: (2020)

Polygenic risk scores and rheumatic diseases
por: Brown, Matthew A., et al.
Publicado: (2021)

New prevention scenarios: polygenic risk
por: Boccanelli, Alessandro, et al.
Publicado: (2021)

Polygenic Risk of Hypertriglyceridemia Is Modified by BMI
por: Esteve-Luque, Virginia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kmt8ufp8ddm83l2ktatn0peb40